Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

721
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
721
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

544
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
544
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Tumor Progression02:07

Tumor Progression

6.6K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advanced Automated Model for Robust Bone Marrow Segmentation in Whole-body MRI.

Academic radiology·2025
Same author

Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study.

Leukemia·2025
Same author

Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial.

Blood·2025
Same author

Radiomics and Artificial Intelligence Landscape for [<sup>18</sup>F]FDG PET/CT in Multiple Myeloma.

Seminars in nuclear medicine·2024
Same author

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.

The New England journal of medicine·2024
Same journal

Der Radiologe·2024
Same journal

Der Radiologe·2024
Same journal

Der Radiologe·2024
Same journal

Der Radiologe·2024
Same journal

Der Radiologe·2022
Same journal

Der Radiologe·2022
See all related articles

Related Experiment Video

Updated: Oct 8, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.0K

[Clinical update-multiple myeloma].

Hartmut Goldschmidt1

  • 1Medizinische Klinik V, Universitätsklinikum Heidelberg und Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland. hartmut.goldschmidt@med.uni-heidelberg.de.

Der Radiologe
|December 30, 2021
PubMed
Summary
This summary is machine-generated.

Multiple myeloma (MM) treatment has evolved from palliative care to managing it as a chronic disease. Advances in diagnostics and novel therapies, including immunotherapy and cell-based treatments, have significantly improved patient prognosis.

Keywords:
Bone marrowMagnetic resonance imagingMalignant plasma cellsPositron emission tomography/computed tomographyPrognosis

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.2K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.6K

Related Experiment Videos

Last Updated: Oct 8, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.0K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.2K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.6K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Multiple myeloma (MM) is a plasma cell malignancy causing bone destruction, bone marrow dysfunction, and renal failure.
  • Historically, MM treatment was primarily palliative, with limited therapeutic options.

Purpose of the Study:

  • To review the evolution of multiple myeloma diagnostics and therapeutics.
  • To highlight recent advancements and their impact on patient outcomes.

Main Methods:

  • Review of classic and modern MM therapies, including chemotherapy, stem cell transplantation, immunomodulators, proteasome inhibitors, and monoclonal antibodies.
  • Description of diagnostic advancements, including serum free light chain assays, imaging (MRI, PET/CT), and cytogenetics (iFISH).

Main Results:

  • Therapeutic landscape shifted from palliative care to managing MM as a chronic condition.
  • Introduction of novel agents and targeted therapies has significantly improved MM patient prognosis.
  • Advanced imaging and molecular diagnostics enable earlier detection and personalized treatment strategies.

Conclusions:

  • MM is increasingly manageable as a chronic disease due to therapeutic and diagnostic progress.
  • Ongoing research into BCMA-targeted therapies, bispecific antibodies, and CAR T-cell therapy promises further improvements in MM treatment.
  • The integration of novel diagnostics and therapies has transformed MM management and patient outcomes.